Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 extension study in progressive supranuclear palsy
NCT06235775Phase 2Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Sep 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tertomotide in progressive supranuclear palsy (PSP), sponsored by GemVax & KAEL Co., Ltd. Primary endpoints: Adverse Event at 12 months, White Blood Cell Count at 12 months and 31 more. Started Dec 2023; status: completed.
02
Drugs
tertomotide
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT06235775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235775.